Antiphospholipid antibodies in COVID-19 are mainly directed against β2GPI but show an epitope specificity different from antibodies in antiphospholipid syndrome (directed against β2GPI domain one, which is strongly correlated with the risk of thrombosis) [126, 127]. This evidence concerns the gene APOH and antiphospholipid syndrome.